Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Dexcom (DXCM) Cost of Revenue (2016 - 2026)

Dexcom has reported Cost of Revenue over the past 17 years, most recently at $441.6 million for Q1 2026.

  • Quarterly Cost of Revenue fell 1.21% to $441.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.9 billion through Mar 2026, up 10.22% year-over-year, with the annual reading at $1.9 billion for FY2025, 16.64% up from the prior year.
  • Cost of Revenue was $441.6 million for Q1 2026 at Dexcom, down from $466.9 million in the prior quarter.
  • Over five years, Cost of Revenue peaked at $477.9 million in Q3 2025 and troughed at $230.7 million in Q1 2022.
  • The 5-year median for Cost of Revenue is $377.6 million (2024), against an average of $368.0 million.
  • Year-over-year, Cost of Revenue surged 43.2% in 2022 and then decreased 1.21% in 2026.
  • A 5-year view of Cost of Revenue shows it stood at $273.9 million in 2022, then soared by 37.97% to $377.9 million in 2023, then grew by 21.12% to $457.7 million in 2024, then grew by 2.01% to $466.9 million in 2025, then fell by 5.42% to $441.6 million in 2026.
  • Per Business Quant, the three most recent readings for DXCM's Cost of Revenue are $441.6 million (Q1 2026), $466.9 million (Q4 2025), and $477.9 million (Q3 2025).